Magicell–NK (Natural killer cells)
Natural killer cells, or NK cells, are lymphocytes in the innate immune system that form the first line of defense against diseases such as cancer, ageing and infections. It detects early signs of cancer and controls them by limiting their spread. In clinical studies, it is observed that the NK cells of cancer patients either decrease in number or in activity. When this happens, these NK cells could not effectively respond to tumor formation and thus is ineffective in killing these cancerous cells.
Magicell-NK is the new generation natural killer cell therapy product developed by MBC. We have confirmed that Magicell-NK can attack human tumors in several cell line models, including liver cancer, colon cancer, kidney cancer, and lung cancer. Through our own Immune Competence Profile, we can evaluate if a patient is suitable to proceed cell therapy. The cell products produced by MBC’s laboratory units which comply with international ISO regulations, and is pending for GTP certification by authorities. We are sending our treatment plans for review under the new amendment issued by the Ministry of Health and Welfare (MOHW). Also, phase I trial for patients with Stage II and III colorectal cancer is expected to initiate in 2019. We cooperate with hospitals wholehearted with a vision to provide the most outstanding technology, products, and services, making every possible endeavor to fight for patients’ life and dignity.